Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)

NCT01956812 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01956812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01956812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Terminated
Start date
December 31, 2013
Completion date
November 30, 2016
Enrollment
334 (actual)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer, pancreatic cancer